Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics

(2011) B. Venugopal et al.   CURRENT MEDICINAL CHEMISTRY

Multikinase inhibitors in thyroid cancer

(2010) Lisa Licitra et al.   EUROPEAN JOURNAL OF CANCER

Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience

(2010) Maria E. Cabanillas et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

(2010) Keith C Bible et al.   LANCET ONCOLOGY

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment

(2009) Keiran SM Smalley et al.   Future Oncology

Dual Inhibition of Mitogen-Activated Protein Kinase Kinase and Mammalian Target of Rapamycin in Differentiated and Anaplastic Thyroid Cancer

(2009) Ning Jin et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors inBRAFMutant Thyroid Carcinoma Cells

(2009) Paolo Salerno et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer

(2009) Martin J. Schlumberger et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct Genetic Alterations in the Mitogen-Activated Protein Kinase Pathway Dictate Sensitivity of Thyroid Cancer Cells to Mitogen-Activated Protein Kinase Kinase 1/2 Inhibition

(2009) Rebecca E. Schweppe et al.   THYROID

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

(2008) Hironobu Minami et al.   CANCER SCIENCE

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies

(2008) Robert C Smallridge et al.   ENDOCRINE-RELATED CANCER

Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification

(2008) Rebecca E. Schweppe et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Lack of Therapeutic Effect of the Histone Deacetylase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma

(2008) Jennifer A. Woyach et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

(2008) Ezra E.W. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Sorafenib in Advanced Thyroid Cancer

(2008) Vandana Gupta-Abramson et al.   JOURNAL OF CLINICAL ONCOLOGY

Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer

(2008) Steven I. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE